Developing artificial intelligence tools for institutional review board pre-review: A pilot study on ChatGPT's accuracy and reproducibility

Short title：AI tools for IRB pre-review: ChatGPT's accuracy and reproducibility

Yasuko Fukataki[1,2]*, Hayashi Wakako[1], Nishimoto Naoki[3], Yoichi M. Ito[1,3]

[1]Health Data Science, Department of Social Science, Graduate School of Medicine, Hokkaido University, Sapporo, Japan

[2] Biostatistics and Data Management, Sapporo Medical University, Sapporo, Japan

[3]Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Japan

Abstract

This pilot study is the first phase of a broader project aimed at developing an explainable artificial intelligence (AI) tool to support the ethical evaluation of Japanese-language clinical research documents. The tool is explicitly not intended to assist document drafting. We assessed the baseline performance of generative AI—Generative Pre-trained Transformer (GPT)-4 and GPT-4o—in analyzing clinical research protocols and informed consent forms (ICFs). The goal was to determine whether these models could accurately and consistently extract ethically relevant information, including the research objectives and background, research design, and participant-related risks and benefits. First, we compared the performance of GPT-4 and GPT-4o using custom agents developed via OpenAI's Custom GPT functionality (hereafter "GPTs"). Then, using GPT-4o alone, we

compared outputs generated by GPTs optimized with customized Japanese prompts to those

generated by standard prompts. GPT-4o achieved 80% agreement in extracting research objectives

and background and 100% in extracting research design, while both models demonstrated high

reproducibility across ten trials. GPTs with customized prompts produced more accurate and

consistent outputs than standard prompts. This study suggests the potential utility of generative AI in

pre-institutional review board (IRB) review tasks; it also provides foundational data for future

validation and standardization efforts involving retrieval-augmented generation and fine-tuning.

Importantly, this tool is intended not to automate ethical review but rather to support IRB

decision-making. Limitations include the absence of gold standard reference data, reliance on a

single evaluator, lack of convergence and inter-rater reliability analysis, and the inability of AI to

substitute for in-person elements such as site visits.

Author summary

In this pilot study, we examined whether ChatGPT could accurately and consistently extract key

elements from clinical research protocols and informed consent forms written in Japanese. These

elements include the research objectives and background, research design, and participant-related

risks and benefits, all essential for ethical review. This study is part of a larger project aiming to

develop an explainable AI tool to assist institutional review board (IRB) members in evaluating

clinical research documents, but not to automate ethical review. As a prerequisite for implementing

advanced technologies such as document retrieval and task-specific adaptation, this study evaluated

the basic capabilities of current large language models. We compared standard and customized

prompts for GPT-4 and GPT-4o and found that GPT-4o, when guided by customized prompts,

produced more accurate and consistent outputs. However, study limitations remain, including the

absence of gold standard reference data, reliance on a single evaluator, and lack of convergence and

inter-rater reliability analysis. This study offers important early insights into how generative AI could

assist the ethical evaluation of clinical research documents written in Japanese.

Introduction

An ethical review of clinical research is essential to ensure both participant safety and research

reliability. Committees responsible for ethical review evaluate the appropriateness of study protocols

and establish standards to safeguard human rights and safety. However, the review processes of

institutional review boards (IRBs) worldwide, as well as certified review boards (CRBs) in Japan,

face several persistent challenges. For instance, review comments from Japan's CRBs show

substantial variation in terms of level of detail, structural organization, and evaluative consistency.

Some CRBs use free-form formats, in which statements may be extremely brief (e.g., "no issues") or

reflect differing evaluative perspectives and address different elements, even among reviewers in the

same field. This variability stems from the absence of a uniform structure. In contrast, other CRBs

produce reviews that are clearly organized by key elements such as research objectives, study design,

and risk–benefit assessment. These disparities have prompted calls to standardize and harmonize the

quality of ethical reviews [1–7].Across different ethics review committees internationally,

considerable variation has been reported in revision instructions and review durations for clinical

research protocols and informed consent forms (ICFs) [8–10]. Such inter-committee variability

undermines the consistency and transparency of the review process and often stems from differing

interpretations of ethical standards and shortages in expert human resources. Delays in the review

process can also postpone study initiation and, in turn, the introduction of new therapies and medical

technologies. Moreover, if revision comments based on ethical standards are inadequate or

inappropriate, they may lead to insufficient or improper amendments to protocols and ICFs,

potentially compromising participant safety.

Recent advances in large language models (LLMs), machine learning, deep learning, and generative

artificial intelligence (AI) have shown promise in medical domains such as image analysis, electronic

health record interpretation, and virtual health assistants [11–17]. LLMs, a type of deep

learning-based generative AI, are capable of performing natural language processing (NLP) tasks

[18]. ChatGPT, a widely known example of generative AI, has been trained on a large corpus of text

and is capable of performing complex natural language tasks [19]. For instance, ChatGPT achieved

scores at or above the passing threshold on publicly available questions from the United States

Medical Licensing Examination (USMLE) [20] and the Japanese National Medical Licensing

Examination [21,22], demonstrating its potential in high-level medical knowledge tasks.

Despite these promising capabilities, generative AI outputs are known to be prone to bias and

hallucinations, raising ethical concerns [23–26]. In healthcare applications, AI transparency and

reliability are crucial [24,25], and explainability is increasingly emphasized [23,26]. Explainable AI

refers to technologies that enable AI to present the reasoning behind its outputs, thereby increasing

the trustworthiness of the system.

Notably, few studies have examined the application of generative AI to the IRB review process itself.

One key barrier is the high confidentiality of documents such as study protocols and ICFs, which

makes it inappropriate to analyze them using cloud-based generative AI models (e.g., ChatGPT,

Gemini, Copilot). Furthermore, IRB reviews typically involve complex deliberation by multiple

experts with extensive experience and knowledge [1,27–29], and it remains unclear whether AI can

adequately replicate such multifaceted processes.

Godwin et al. developed an AI tool to support the drafting of IRB application documents, seeking to

improve the efficiency of document-preparation processes [30]. However, this approach is limited to

assisting the creation of application materials and is not intended to support the process of reviewing

submitted documents.

In contrast, the present project aims to develop an explainable AI tool to support the IRB document

review process. Specifically, the system is designed to provide both the evaluation results—namely,

which key elements the AI identified as critical for comprehensive IRB review, including research

objectives and background, study design, participant-related risks and benefits, and other

domain-specific considerations such as data management, statistical methodology, clinical expertise,

and pharmacological perspectives—and the reasoning behind those evaluations. The goal is to assist

IRB members in their decision-making and to improve the efficiency and consistency of the

document review process. Importantly, this project does not aim to automate the IRB review; rather,

it is based on the premise that AI should serve as a supporting tool for human reviewers.

The implementation of such AI support tools will eventually require advanced techniques such as

retrieval-augmented generation (RAG) and fine-tuning (FT). However, it is first necessary to

evaluate whether existing generative AI models can accurately and reproducibly extract key

information from Japanese clinical research documents. Without this foundational capability,

subsequent technological enhancements would lack reliability.

Accordingly, this article reports a foundational pilot study within our broader project. The overall

structure of the project and the role of this study are illustrated in Fig 1.

Fig 1. Project Overview and the Position of this Study in Developing an AI-based IRB Review Support
System.
This figure illustrates the broader framework for building an explainable AI tool to support document review in
IRB processes. This pilot study serves as the first phase, evaluating the baseline accuracy and reproducibility of
generative AI models in extracting and summarizing key components—namely, research objectives and
background, research design, and participant-related risks and benefits—from clinical research protocols and ICFs.

In this study, we examined whether ChatGPT could accurately and reproducibly extract and

summarize these key elements from Japanese-language documents. The findings are intended to

serve as foundational data for the future implementation of RAG and FT technologies. Notably, this

study does not evaluate the ability of AI to make judgments based on review criteria or to explain

those judgments; such evaluation is planned in subsequent phases of the project.

We conducted two primary comparisons:

(1) a performance comparison between GPT-4 and GPT-4o;

(2) a reproducibility comparison between customized GPTs (modified via prompt engineering,

without FT) and standard prompts.

Results

In this study, we developed four customized GPT models (GPTs-1 to GPTs-4) using GPT-4 and

GPT-4o to extract and summarize key components from Japanese clinical research protocols and

ICFs. The target elements were: (1) research objectives and background, (2) research design, and (3)

participant-related risks and benefits. We compared the accuracy and reproducibility of both models,

and additionally evaluated the reproducibility of outputs generated using customized GPTs versus

standard prompts.

Accuracy evaluation

GPT-4o achieved 80% extraction accuracy for the "research objectives and background" element,

and 100% extraction accuracy for both "research design" and "participant-related risks and benefits"

(Table 1).

In contrast, GPT-4 achieved only 30% extraction accuracy for "research objectives and background"

but demonstrated 100% extraction accuracy for the other two elements (Table 2).

Table 1. Accuracy of Information Extraction by GPT-4o: Extraction Accuracy with Research

Protocol and ICF (10 Trials).

GPTs	Item	Accuracy	Partial Accuracy

GPTs-1	Research objectives and background	80	20
GPTs-2	Research design	100	0
GPTs-3	Participant-related risks and benefits (RP)	100	0
GPTs-4	Participant-related risks and benefits (ICF)	100	0

RP = research protocol; ICF = informed consent form.

This table presents the extraction accuracy and partial extraction accuracy rates across 10 trials for each GPT (GPTs-1 to GPTs-4). All values are shown as percentages.

Table 2. Accuracy of Information Extraction by GPT-4: Extraction Accuracy with Research Protocol and ICF (10 Trials).

GPTs	Item	Accuracy (%)	Partial Accuracy (%)
GPTs-1	Research objectives and background	30	70
GPTs-2	Research design	100	0
GPTs-3	Participant-related risks and benefits (RP)	100	0
GPTs-4	Participant-related risks and benefits (ICF)	100	0

RP = research protocol; ICF = informed consent form.

This table presents the extraction accuracy and partial extraction accuracy rates across 10 trials for each GPT (GPTs-1 to GPTs-4). All values are shown as percentages.

Reproducibility evaluation

Both models demonstrated high reproducibility, with at least 8 out of 10 outputs from each GPT

rated as "consistent" or "partially consistent" (Table 3).

Table 3. Reproducibility of Information Extraction by GPT-4 and GPT-4o: Consistency Across 10 Trials.

GPTs	Item	GPT-4o	GPT-4
GPTs-1	Research objectives and background	High	High
GPTs-2	Research design	High	High
GPTs-3	Participant-related risks and benefits of research protocol	High	High

GPTs-4	Participant-related risks and benefits of ICF	High	High

149 This table summarizes the reproducibility results for each GPT (GPTs-1 to GPTs-4) based on 10 trials.

150 Reproducibility was defined as "high" when 8 or more trials were rated as "consistent" or "partially consistent."

151 Both GPT-4o and GPT-4 demonstrated equally high reproducibility across all tasks, with no notable differences

152 observed between the models.

Comparison Between Customized GPTs and Standard Prompts

Outputs generated using customized GPTs consistently produced exactly two well-structured

participant-related benefit statements in each trial:

(1) Enhancement of information collection and follow-up care

(2) Expansion of treatment options

In contrast, outputs generated using standard prompts showed greater variability in both the number

and type of extracted participant-related benefits, with categories and counts differing significantly

across trials (Tables 4 and 5).

Table 4. Number of Participant-Related Benefits Extracted by GPTs vs. Standard Prompts:

Comparison Across 10 Trials Using GPT-4o.

Prompt Type	Number of trials	Extracted participant-related benefits			
		Mean	SD	Max	Min
GPTs-3	10	2.0	0.0	2	2
Standard prompts	10	5.3	1.8	8	3

164 This table compares the mean, standard deviation, maximum, and minimum number of participant-related benefit

165 statements extracted by GPTs-3 and standard prompts using GPT-4o.

166 **Table 5. Categories of Participant-Related Benefits Extracted by GPTs vs. Standard Prompts:**

167 **Comparison Across 10 Trials Using GPT-4o.**

Category	GPTs-3	Standard prompts
Detailed information collection and follow-up care	Extracted	Extracted

Increase in treatment options	Extracted	Extracted
Reduction of economic burden	Not extracted	Extracted
Compensation for health risks	Not extracted	Extracted
Provision of personalized treatment	Not extracted	Extracted
Cost-effective treatment	Not extracted	Extracted
Evaluation of treatment efficacy and safety	Not extracted	Extracted
Collection and analysis of clinical data	Not extracted	Extracted
Protection of personal information	Not extracted	Extracted
Improvement in quality of life	Not extracted	Extracted

This table presents the output categories of participant-related benefits statements generated by GPTs-3 and
standard prompts. "Extracted" indicates that a given category appeared at least once during the 10 trials; "Not
extracted" indicates that the category was never generated. GPTs-3, with clearly defined instructions and output
formats, consistently extracted participant-related benefits explicitly described in the research protocol. In contrast,
the outputs from standard prompts—due to their unstructured format—showed a wider and more diverse set of
categories.

Discussion

This pilot study evaluated the accuracy and reproducibility of ChatGPT models (GPT-4 and GPT-4o)

in extracting and summarizing content from Japanese-language research protocols and ICFs. The aim

was to assess the foundational capabilities of LLMs in preparation for their potential use in

supporting IRB document review.

The results showed that GPT-4o achieved 80% extraction accuracy for the "research objectives and

background" element and 100% extraction accuracy for both "research design" and

"participant-related risks and benefits," demonstrating higher baseline accuracy than GPT-4. Notably,

both models achieved perfect extraction accuracy for research design. However, some

misinterpretations of medical terminology were observed. For example, "trastuzumab BS" was

shortened to "trastuzumab," indicating inconsistencies in the handling of similar or abbreviated terms.

These variations suggest that the model's interpretation of synonyms and abbreviations requires

refinement, potentially through the application of RAG and FT.

Reproducibility was also high for both models, with 8 or more out of 10 outputs rated as "consistent"

or "partially consistent" across all GPT variants. In particular, GPTs-3, which focused on extracting

participant-related risks and benefits, outperformed standard prompts by providing more accurate

and consistent results. Specifically, the participant-related benefits of "improved follow-up care" and

"expanded treatment options" were consistently extracted in all 10 trials.

By contrast, outputs generated using standard prompts showed greater variation in both the number

and category of extracted participant-related benefits. This discrepancy is likely due to the

effectiveness of prompt engineering, which explicitly defined the document sections to be referenced,

the target elements to be extracted, and the output format. These findings highlight the critical role of

prompt design in improving the accuracy and reproducibility of information extraction from

Japanese-language documents. Based on these foundational performance results, further

enhancement of AI models through RAG and FT is expected to support the practical implementation

of AI tools for IRB review.

This study specifically assessed whether ChatGPT could extract and summarize critical

information—namely, the research objectives and background, research design, and

participant-related risks and benefits —that are essential for IRB document review. The findings

demonstrated that current models possess sufficient baseline performance in terms of accuracy and

reproducibility to support document-level review tasks. These results provide a basis for the future

integration of advanced techniques such as RAG and FT.

Reproducibility and accuracy remain critical challenges for AI in healthcare. For example, research

has highlighted the problem of inconsistent AI outputs across different datasets and conditions,

presenting a barrier to clinical implementation [31]. The findings of this study align with such

concerns, reinforcing that reproducibility and accuracy must be carefully balanced even in AI

applications for document analysis.

From a technical perspective, we observed that ChatGPT struggled with PDF files that had complex

structures or contained text stored as images. However, converting these documents to Word format

and standardizing the heading structures significantly improved output stability. These results

suggest that standardizing document formats is essential for ensuring accurate and reliable

AI-assisted reviews.

Limitations

This study is positioned as a foundational pilot evaluation to assess the applicability of ChatGPT in

supporting pre-reviews by IRBs, prior to the implementation of more advanced techniques such as

RAG and FT.

The primary key performance indicators (KPIs) in this study were accuracy and reproducibility,

focusing specifically on the quality of outputs extracting and summarizing the research objectives

and background, research design, and participant-related risks and benefits. These KPIs were

preliminarily established based on elements considered critical in IRB reviews; however, they should

be further refined in future studies.

As a pilot study, the evaluation was conducted under practical constraints using manual review by a

single assessor. This approach was chosen as a simple and pragmatic method for basic validation and

was intended to provide foundational data for applying more advanced evaluation techniques in the

next research phase.

Importantly, no formal benchmark—such as comparison with human IRB assessments—was applied at

this stage. This limitation reflects the proof-of-concept nature of the study and will be addressed

in the next phase of research.

Nevertheless, the following limitations must be acknowledged.

1. Absence of gold standard reference data and unestablished evaluation criteria

In this study, we manually compared ChatGPT's outputs with the original research protocol and ICF

texts, assessing output accuracy and reproducibility based on predefined criteria.

Table 6 presents the detailed criteria for evaluating output accuracy, including content accuracy,

semantic consistency, and expression consistency.

Table 7 outlines the classification standards for categorizing outputs into "consistent," "partially

consistent," or "inconsistent" based on the predefined accuracy evaluation criteria.

Table 8 presents the evaluation criteria for reproducibility, categorizing outputs into high, moderate,

or low reproducibility based on the number of trials rated as "consistent" or "partially consistent."

Table 6. Criteria for Evaluating Output Accuracy."

Item	Condition
Content accuracy	・Specific numerical values match perfectly. ・All major information related to research objectives and background is included. ・All major information related to research design and methods is included.
Semantic consistency	The meaning and intent of the original document are accurately conveyed.
Expression consistency	Even if phrasing or word choices differ, the meaning and intent remain unchanged (e.g., the number of patients increased" vs. "patient numbers increased").

243 This table defines the criteria used to assess the accuracy of GPT outputs compared with the research protocol and
244 ICFs, encompassing content accuracy, semantic consistency, and expression consistency.

245 **Table 7. Classification Criteria for Output Accuracy.**

Evaluation criteria	Description
Consistent	The output content matches the content of the research protocol completely and without error.
Partially consistent	The major information and intent of the output are mostly consistent with the research protocol. Minor discrepancies are observed, but these do not significantly impair the accuracy of the information, nor alter the meaning or intent.
Inconsistent	The output content does not match the major content of the research protocol, resulting in significant impairment of information accuracy or alteration of meaning or intent.

246 This table outlines the standards for classifying GPT outputs into "consistent," "partially consistent," or
247 "inconsistent" categories based on the predefined accuracy evaluation criteria.

248 **Table 8. Evaluation Criteria for Reproducibility.**

Reproducibility level	Description
High	When 8 or more out of 10 trials are judged as "consistent" or "partially consistent" in line with Tables 7 and 8.
Moderate	When 5 to 7 out of 10 trials are judged as "consistent" or "partially consistent" in line with Tables 7 and 8.

Low	When 4 or fewer out of 10 trials are judged as "consistent" or "partially consistent" in line with Tables 7 and 8.

This table classifies the reproducibility of GPT model outputs into three categories based on how many trials were

rated as "consistent" or "partially consistent" (see Tables 7 and 8):

• ≥8 trials: High reproducibility

• 5–7 trials: Moderate reproducibility

• ≤4 trials: Low reproducibility

Limitations:

• **Lack of gold standard reference data:**

Because publicly available IRB review results were not validated for correctness, we could

not assess ChatGPT's accuracy through direct comparison with a verified reference set.

• **Preliminary KPIs and evaluation criteria:**

In this study, the evaluation criteria and KPIs were preliminarily established by focusing on

key elements considered important in IRB document review—namely, the research objectives

and background, research design, and participant-related risks and benefits.

The purpose was to assess the accuracy and reproducibility of extracting and summarizing

these elements as a preliminary validation.

Since this study only targeted a limited set of elements, it remains necessary to further

examine whether these KPIs are sufficient for broader IRB document review.

Because standardized benchmarks for such evaluations do not yet exist, future studies should

aim to validate these KPIs and establish standardized evaluation methods.

• **Single evaluator and lack of inter-rater agreement:**

The evaluation was conducted by a single researcher, and inter-rater agreement was not

assessed. Consequently, subjective judgments may have introduced bias in the results.

Future directions: To enhance objectivity and statistical validity, future research will adopt the

following strategies:

• Inter-rater reliability analysis using multiple evaluators (e.g., Cohen's kappa);

• Quantitative NLP-based metrics (e.g., BLEU, ROUGE, Sentence-BERT similarity scores);

• Comparison with established review criteria (to assess alignment of AI outputs with ethical

standards);

• Validation by IRB members.

These approaches will help develop appropriate evaluation frameworks for AI in IRB pre-review

settings, especially when gold standard reference data are unavailable. In particular, directly

comparing AI-generated outputs with assessments by experienced IRB reviewers will be essential for

validating the practical utility of AI in ethical review, especially the degree to which AI tools can

reflect the nuanced and context-sensitive judgments made by human experts.

2. Unvalidated trial count

In this proof-of-concept pilot study, 10 trials were conducted per task to assess output stability and

reproducibility. This number was pragmatically selected to capture practical variation and trends in

AI-generated outputs. The appropriateness of this trial count was not statistically validated, and no

power analysis or convergence testing was conducted. This decision aligns with previous

methodological recommendations for pilot studies, which emphasize feasibility testing and suggest that rigorous sample size calculations are not necessarily required in such contexts [32, 33].

Future directions: Future studies will address this limitation through the following analyses:

- **Convergence analysis:** Evaluating output stability as the number of trials increases;

- **Confidence interval estimation:** Quantifying how variation in trial count affects reproducibility.

These analyses will inform the establishment of appropriate trial counts for evaluating AI-assisted IRB pre-reviews.

3. Lack of API-based logging

This study did not use the ChatGPT API, meaning that model usage (GPT-4 vs. GPT-4o), prompt details, execution timestamps, and output results were not automatically logged for each session. While the research team manually recorded the model used in each session and determined that this did not significantly affect the reliability of the results, the lack of automatic logs limits the objectivity, reproducibility, and transparency of the study.

In future studies, we plan to implement automated session logging using the API. This will enable systematic recording of model usage, prompt content, execution timing, and output results, thereby significantly improving the efficiency, completeness, and transparency of data collection and analysis.

4. Exclusion of judgment-based review components from evaluation

Finally, this study targeted the document-based IRB/CRB review process in Japan and was not intended to replace procedures requiring in-person assessment or site visits. When considering the application of AI to IRB processes in other countries, it will be necessary to examine whether AI can reasonably support judgment-based components of review—such as face-to-face meetings and site inspections—in addition to document-based assessments.

Materials and methods

Study overview

This study evaluated the accuracy and reproducibility of outputs generated by GPT models (OpenAI, San Francisco, CA, USA) in the document review of research protocols and ICFs. With a view toward future implementations of AI in supporting document-based IRB reviews in Japan, we focused on processing Japanese-language protocols using prompts written in Japanese.

Two types of comparisons were conducted:

1. a performance comparison between GPT-4 and GPT-4o (the latest model as of May 2024);

2. a reproducibility comparison between customized GPTs and standard prompts,

The primary KPIs were the accuracy and reproducibility of information extraction by AI for three elements:

1. research objectives and background;

2. research design;

3. participant-related risks and benefits.

These evaluation categories were preliminarily defined by focusing on three key
elements considered important in IRB document review-namely, research objectives and
background, research design, and participant-related risks and benefits.
This pilot study specifically assessed the accuracy and reproducibility of extracting
and summarizing these limited elements.
Since the study targeted only a subset of information typically reviewed by IRB members,
the KPIs used here are provisional and will be refined through future studies.
No FT or parameter adjustments were applied to the models. Instead, evaluation was
conducted solely using prompt engineering with the default configuration provided by
OpenAI.

Data source

Mock review materials publicly available from the Ministry of Health, Labour and Welfare of Japan

were used for this study [34]. These materials were created for training and education on IRB review

and include fictional protocols and corresponding mock evaluation results across 10 disease domains

[35-38].

Specifically, the dataset includes:

• Ten research projects covering oncology (n=3), gastrointestinal diseases (n=1), rheumatoid

arthritis (n=1), vaccines (n=1), medical devices (n=1), cardiovascular diseases (n=1),

pediatric psychiatric disorders (n=1), and cognitive impairment (n=1).

• Each set contains research protocols, explanatory documents, monitoring manuals, audit

manuals, and expert reviewer reports (mock IRB assessments).

The validity of the mock evaluations is not disclosed, so the materials were used as reference

standards, not as absolute ground truth.

For this study, we selected and analyzed the following protocol:

"Phase II trial of trastuzumab for patients with advanced solid tumors without standard treatment options" (Mock Review No. 1)

Model selection and configuration

We evaluated the performance of the GPT-4 and GPT-4o models. GPT-4 is a conventional high-performance model with strong capabilities across a range of text generation tasks [39]. GPT-4o, released on May 13, 2024, offers twice the speed and 50% lower cost compared to GPT-4 Turbo. GPT-4o also achieves state-of-the-art performance in speech recognition, multilingual processing, and visual capabilities. In particular, improvements in multilingual capabilities allow for higher accuracy when processing non-English texts [40]. Given these characteristics, we considered it valuable to verify the accuracy improvements offered by GPT-4o.

We did not apply FT or model parameter adjustments. Instead, we used the GPTs feature provided by OpenAI [41] to develop customized GPTs tailored to extract specific categories of information (Table 9).

Table 9. Overview of the Four Customized GPTs and Their Prompt Structures.

GPTs	Overview of prompts
GPTs-1	Accurately extract the research objectives and background from the provided research protocol.
GPTs-2	Accurately extract details such as target patients, trial phase, trial type, randomization, control group setup, blinding, and sample size.
GPTs-3	Accurately extract the participant-related risks and benefits for the subjects from sections 16.3.1 and 16.3.2 of the research

	`protocol.`
`GPTs-4`	`Accurately extract the participant-related risks and benefits for the subjects from section 6 of the ICF.`

This table summarizes the four customized GPTs (GPTs-1 to GPTs-4) developed for information extraction from research protocols and informed consent forms (ICFs). Each GPT was designed to target a specific document type and extraction goal aligned with one of the evaluation categories: research objectives and background, research design, and participant-related risks and benefits.

Evaluation process and comparison

Procedure for GPTs trials

To assess accuracy and reproducibility, the following procedure was implemented:

1. **Start a new chat session**

   Each trial was initiated in a new session to eliminate any influence from previous interactions.

2. **Select model and GPT**

   GPT-4 or GPT-4o was selected along with one of the four customized GPTs (GPTs-1 to GPTs-4).

3. **Upload document**

   The target research protocol or ICF was uploaded, then outputs were automatically generated using the embedded prompts.

4. **Save output**

   Each result was saved with a name format such as "GPTs_name_trialNumber." All outputs were evaluated after completing 10 trials for each GPT.

5. **Repeat process**

385   Each GPT was run 10 times with both models, totaling 80 trials.

Procedure for standard prompt trials

For comparison, we also conducted evaluations using standard prompts.

1. **Start a new chat session**

Each trial was conducted in an independent session.

2. **Model selection**

The GPT-4o model was used.

3. **Upload document and enter prompt**

The research protocol or ICF was uploaded. The following prompt (in Japanese) was

entered:

"You are an IRB reviewer. Please extract the participant-related benefits for participants

from the following research protocol."

4. **Save output**

Each result was saved as "StandardPrompt_trialNumber" and evaluated after all 10 trials

were completed.

5. **Repeat process**

A total of 10 trials were performed.

Evaluation criteria for accuracy and reproducibility

403   All outputs were manually reviewed by one evaluator based on predefined criteria (Tables 6 to 8)

using the following process:

1. Accuracy

Outputs were classified as "consistent," "partially consistent," or "inconsistent" using the definitions

presented in Tables 6 and 7.

2. Reproducibility

Reproducibility was determined based on the criteria presented in Table 8, using the number of trials

rated as "consistent" or "partially consistent" per model (out of 10).

The extracted text and its translation, GPT-generated outputs, results from standard prompts, and the

mock IRB evaluation form are provided as supporting information (S1 to S11 Files) to ensure

transparency and reproducibility.

Acknowledgments

We would like to express our gratitude to Associate Professor Kenji Hirata from the Department of

Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, for providing valuable

insights related to this project. We also thank Professor Shiro Hinotsu from the Division of

Biostatistics and Data Management, Sapporo Medical University, for dedicating his time to

discussing this topic with us.

We thank ChatGPT (OpenAI) for assisting with the English translation of Japanese-language

research materials, including manuscript drafts, mock protocols, and output examples. All

AI-generated translations were carefully reviewed and verified by the authors. We also thank Editage

423 (Cactus Communications) for providing final English proofreading.

424 The authors take full responsibility for the accuracy and integrity of the manuscript content.

References

1. Ministry of Health, Labour and Welfare (MHLW). [Minutes of the 2nd Clinical Research

Subcommittee Meeting of the Health Science Council]. 2017 Aug 31 [cited 2025 Jun 15].

Available from: https://www.mhlw.go.jp/stf/shingi2/0000179030.html. Japanese.

2. MHLW. [Minutes of the 10th Clinical Research Subcommittee Meeting of the Health Science

Council]. 2019 Feb 15 [cited 2025 Jun 15]. Available from:

https://www.mhlw.go.jp/stf/newpage_03963.html. Japanese.

3. MHLW. [Document 1 from the 10th Clinical Research Subcommittee Meeting of the Health

Science Council: Summary of discussion points on the promotion of clinical research and

clinical trials]. 2019 Feb 15 [cited 2025 Jun 15]. Available from:

https://www.mhlw.go.jp/stf/newpage_03565.html. Japanese.

4. MHLW. [Minutes of the 34th Clinical Research Subcommittee Meeting of the Health Science

Council]. 2020 Jan 31 [cited 2025 Jun 15]. Available from:

https://www.mhlw.go.jp/stf/newpage_38195.html. Japanese.

5. MHLW. [Document 1 from the 34th Clinical Research Subcommittee Meeting of the Health

Science Council: On certified clinical research review boards]. 2020 Jan 31 [cited 2025 Jun 15].

Available from: https://www.mhlw.go.jp/stf/newpage_37286.html. Japanese.

6. MHLW. [Minutes of the 35th Clinical Research Subcommittee Meeting of the Health Science

Council]. 2020 Aug 8 [cited 2025 Jun 15]. Available from:

https://www.mhlw.go.jp/stf/newpage_43555.html. Japanese.

7. MHLW. [Documents 1–6 from the 35th Clinical Research Subcommittee Meeting of the Health

Science Council: On certified clinical research review boards]. 2020 Aug 8 [cited 2025 Jun 15].

Available from: https://www.mhlw.go.jp/stf/newpage_42147.html. Japanese.

8. Larson E, Bratts T, Zwanziger J, Stone P. A Survey of IRB process in 68 U.S. hospitals. J Nurs

Scholarsh. 2004;36:260-264. doi: 10.1111/j.1547-5069.2004.04047.x.

9. Dyrbye LN, Thomas MR, Mechaber AJ, Eacker A, Harper W, Massie FS Jr, et al. Medical

education research and IRB review: An analysis and comparison of the IRB review process at

six institutions. Acad Med. 2007;82:654-660. doi: 10.1097/ACM.0b013e31806747b8.

10. Abbott L, Grady C. A Systematic Review of the Empirical Literature Evaluating IRBs: What we

know and what we still need to learn. J Empir Res Hum Res Ethics. 2011;6:3-19. doi:

10.1525/jer.2011.6.1.3

11. Haug CJ, Drazen JM. Artificial intelligence and machine learning in clinical medicine, 2023. N

Engl J Med. 2023;388:1201–1208. doi: 10.1056/NEJMp2301212.

12. Nazario-Johnson L, Zaki HA, Tung GA. Use of large language models to predict neuroimaging.

J Am Coll Radiol. 2023;20:1004-1009. doi: 10.1016/j.jacr.2023.06.008.

13. Lee KH, Lee RW, Kwon YE. Validation of a deep learning chest X-ray interpretation model:

integrating large-scale AI and large language models for comparative analysis with ChatGPT.

Diagnostics (Basel). 2023;14:90. doi: 10.3390/diagnostics14010090.

14. Denecke K, May R, Rivera Romero O, LLM Health Group. Potential of large language models

in health care: Delphi Study. J Med Internet Res. 2024;26:e52399. doi: 10.2196/52399.

15. Hirosawa T, Harada Y, Tokumasu K, Ito T, Suzuki T, Shimizu T. Evaluating ChatGPT-4's

diagnostic accuracy: Impact of visual data integration. JMIR Med Inform. 2024;12:e55627. doi:

10.2196/55627.

16. Zhu Q, Chen X, Jin Q, Hou B, Mathai TS, Mukherjee P, et al. Leveraging professional

radiologists' expertise to enhance LLMs' evaluation for radiology reports. arXiv:2401.16578v3

[Preprint]. 2024 [cited 2025 Jun 15]. doi: 10.48550/arXiv.2401.16578.

17. Al Nazi Z, Peng W. Large language models in healthcare and medical domain: A review.

`arXiv:2401.06775v2 [Preprint]. 2024 Jul 8 [cited 2025 Jun 15]. doi:`

`10.48550/arXiv.2401.06775.`

18. Naveed H, Khan AU, Mian A, Saqib M, Anwar S, Usman M, et al. A comprehensive overview

of large language models. arXiv.2307.06435 [Preprint]. 2023 [cited 2025 Jun 15]. doi:

10.48550/arXiv.2307.06435.

19. OpenAI. ChatGPT. OpenAI product page. [cited 2025 Jun 15]. Available from:

https://openai.com/ja-JP/index/chatgpt/

20. Gilson A, Safranek CW, Huang T, Socrates V, Chi L, Taylor RA, et al. How does ChatGPT perform on the United States Medical Licensing Examination (USMLE)? The implications of large language models for medical education and knowledge assessment. JMIR Med Educ. 2023;9:e45312. doi: 10.2196/45312. Erratum in: JMIR Med Educ. 2024;10:e57594. doi: 10.2196/57594.

21. Yanagita Y, Yokokawa D, Uchida S, Tawara J, Ikusaka M. Accuracy of ChatGPT on medical questions in the national medical licensing examination in Japan: Evaluation Study. JMIR Form Res. 2023;7:e48023. doi: 10.2196/48023.

22. Tanaka Y, Nakata T, Aiga K, Etani T, Muramatsu R, Katagiri S, et al. Performance of generative pretrained transformer on the national medical licensing examination in Japan. PLOS Digit Health. 2024;3:e0000433. doi: 10.1371/journal.pdig.0000433.

23. Vainio-Pekka H, Agbese MO, Jantunen M, Vakkuri V, Mikkonen T, Rousi R, et al. The role of explainable AI in the research field of AI ethics. ACM Trans Interact Intell Syst. 2023;13(4):1-39. doi: 10.1145/3599974

24. Jeyaraman M, Balaji S, Jeyaraman N, Yadav S. Unraveling the Ethical Enigma: Artificial Intelligence in Healthcare. Cureus. 2023;15(8):e43262. doi: 10.7759/cureus.43262.

25. Sun Q, Akman A, Schuller BW. Explainable artificial intelligence for medical applications: A review. arXiv:2412.01829 [Preprint]. 2024 [cited 2025 Jun 15]. Available from: https://arxiv.org/abs/2412.01829

26. Tejakusuma IR, Kusumawati YA, Widita A, Maulida FH, Prasetyo FA. Elevating Thematic

Branding through Social Media Content: A Visual Concept of Kayutangan Heritage's Instagram

Feed. In: 2022 4th International Conference on Cybernetics and Intelligent System (ICORIS);

2022 Oct 8; Prapat, Indonesia. IEEE; 2023. pp. 1-6. doi: 10.1109/ICORIS56080.2022.10031457.

27. MHLW. [Document 3 from the 2nd Clinical Research Subcommittee Meeting of the Health

Science Council: On certified clinical research review boards]. 2017 Aug 31 [cited 2025 Jun 15].

Available from: https://www.mhlw.go.jp/stf/shingi2/0000175731.html. Japanese.

28. MHLW. [Minutes of the 5th Clinical Research Subcommittee Meeting of the Health Science

Council]. 2017 Nov 17 [cited 2025 Jun 15]. Available from:

https://www.mhlw.go.jp/stf/shingi2/0000188562.html. Japanese.

29. MHLW. [Document 2 from the 5th Clinical Research Subcommittee Meeting of the Health

Science Council: On certified clinical research review boards]. 2017 Nov 17 [cited 2025 Jun 15].

Available from: https://www.mhlw.go.jp/stf/shingi2/0000184433.html. Japanese.

30. Godwin RC, Bryant AS, Wagener BM, Ness TJ, DeBerry JJ, Horn LL, et al.

IRB-draft-generator: A generative AI tool to streamline the creation of institutional review board

applications. SoftwareX. 2024;25:101601. doi: 10.1016/j.softx.2024.101601

31. Sohn E. The reproducibility issues that haunt health-care AI. *Nature*. 2023;613:402-403. doi:

10.1038/d41586-023-00023-2.

32. Hertzog□MA. Considerations in determining sample size for pilot studies. Res Nurs Health.

2008;31:180-191. doi:10.1002/nur.20247.

33. Julious☐SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat.

2005;4:287-291. doi:10.1002/pst.185.

34. MHLW. [Mock IRB review materials: 2019 mock evaluation cases (Cases 1–5 and 6–10)]. 2019

[cited 2025 Jun 15]. Available from:

https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000163417.html. Japanese.

35. MHLW. [Minutes of the 8th Clinical Research Subcommittee Meeting of the Health Science

Council]. 2018 Dec 5 [cited 2025 Jun 15]. Available from:

https://www.mhlw.go.jp/stf/newpage_02822.html. Japanese.

36. MHLW. [Reference material 3 from the 8th Clinical Research Subcommittee Meeting of the

Health Science Council: On the implementation status of the Clinical Research Act and related

matters]. 2018 Dec 5 [cited 2025 Jun 15]. Available from:

https://www.mhlw.go.jp/stf/newpage_02524.html. Japanese.

37. MHLW. [Minutes of the 9th Clinical Research Subcommittee Meeting of the Health Science

Council]. 2019 Jan 23 [cited 2025 Jun 15]. Available from:

https://www.mhlw.go.jp/stf/newpage_03737.html. Japanese.

38. MHLW. [Document 3 from the 9th Clinical Research Subcommittee Meeting of the Health

Science Council: On efforts to promote clinical research and clinical trials]. 2019 Jan 23 [cited

2025 Jun 15]. Available from: https://www.mhlw.go.jp/stf/newpage_03163.html. Japanese.

39. OpenAI. GPT-4 is OpenAI's most advanced system, producing safer and more useful responses.

OpenAI product page. [cited 2025 Jun 15]. Available from: https://openai.com/ja-JP/index/gpt-4/

40. OpenAI. Hello GPT-4o. OpenAI product page. 2024 May 13 [cited 2025 Jun 15]. Available

from: https://openai.com/index/hello-gpt-4o/

41. OpenAI. Introducing GPTs. OpenAI product page. 2023 Nov 6 [cited 2025 Jun 15]. Available

from: https://openai.com/index/introducing-gpts/

Supporting information

To ensure the transparency and reproducibility of this study, the following materials are provided as

supporting information.

S1 File. List of extracted sections from the research protocol and ICF (Japanese original and

English translation).

This file contains the original Japanese text and English translations of the specific sections from the

research protocol and informed consent form (ICF) that were subject to extraction and

summarization in this study.

S2 File. GPTs-1 output results (GPT-4o model).

A list of outputs generated by GPTs-1 using the GPT-4o model, focusing on the extraction of the

"research objectives and background" element.

S3 File. GPTs-1 output results (GPT-4 model).

A list of outputs generated by GPTs-1 using the GPT-4 model.

S4 File. GPTs-2 output results (GPT-4o model).

A list of outputs generated by GPTs-2 using the GPT-4o model, focusing on extraction of the

"research design" element.

S5 File. GPTs-2 output results (GPT-4 model).

A list of outputs generated by GPTs-2 using the GPT-4 model.

S6 File. GPTs-3 output results (GPT-4o model).

A list of outputs generated by GPTs-3 using the GPT-4o model, focusing on extraction of the

"participant-related risks and benefits" from the research protocol.

S7 File. GPTs-3 output results (GPT-4 model).

A list of outputs generated by GPTs-3 using the GPT-4 model.

S8 File. GPTs-4 output results (GPT-4o model).

A list of outputs generated by GPTs-4 using the GPT-4o model, focusing on extraction of the

"participant-related risks and benefits" from the ICF.

S9 File. GPTs-4 output results (GPT-4 model).

A list of outputs generated by GPTs-4 using the GPT-4 model.

S10 File. Output results using a standard prompt (GPT-4o model).

This file contains the outputs generated using a standard prompt in GPT-4o, used for comparison

with GPTs-based outputs.

S11 File. Mock IRB evaluation form (Japanese only).

This is a publicly available mock IRB evaluation form published by the Ministry of Health, Labour

and Welfare of Japan. It was referenced in determining the provisional KPIs used in this study. Please

note that the correctness of the evaluation results in this form has not been publicly verified, and thus

cannot be directly compared with the AI-generated outputs.

Target Documents:
Clinical Research Protocols / ICFs

Written in Japanese

Pilot Phase (This Study)

- GPT-4 / GPT-4o used for information extraction
- Comparison of custom vs standard prompts
- Key items: Study objectives, design, benefits/risks
- Evaluation of accuracy and reproducibility

Next Phase (Future Work)

- Integration of Retrieval-Augmented Generation (RAG)
- Fine-tuning to improve output quality
- Enhancements: Multi-rater evaluation, quantuitative NLP metrics, API-based logging

Final Goal (Project Objective)

- Develop an explainable AI tool to assist IRB members
- Support consistency, efficiency, and transparency in document review
- Supplement human decision-making (no automation intended)